Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 16/20 | 0.65 |
| ▸ | CYP11B1 | P15538 | 15/20 | 0.65 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980699 | 0.86 | CYP11B1 (0.49) | CYP11B2CYP11B1MAOA | |
| SCHEMBL7282150 | 0.84 | CYP11B2 (0.66) | CYP11B2CYP11B1EGLN2TRPV4 | |
| SCHEMBL18297999 | 0.83 | CYP11B2 (0.67) | CYP11B2CYP11B1TRPV4 | |
| SCHEMBL1514257 | 0.82 | CYP11B1 (0.78) | CYP11B2CYP11B1TRPV4 | |
| SCHEMBL30132416 | 0.82 | CYP11B1 (0.78) | CYP11B2CYP11B1TRPV4 | |
| SCHEMBL9612021 | 0.81 | CYP11B2 (0.68) | CYP11B2CYP11B1TRPV4 | |
| SCHEMBL13885712 | 0.79 | AR (0.65) | CYP11B2CYP11B1 | |
| SCHEMBL8265080 | 0.79 | CYP11B1 (0.65) | CYP11B2CYP11B1 | |
| SCHEMBL28073041 | 0.79 | MAOA (0.47) | CYP11B2CYP11B1MAOA | |
| SCHEMBL1156401 | 0.79 | TRPV4 (0.57) | CYP11B2CYP11B1EGLN2TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642788-B2 | Activators of executioner procaspases 3, 6 and 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-04 | — | — | US | disclosed |
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2237784-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | The Regents of the University of California (US) | 2010-10-13 | — | — | EP | disclosed |
| WO-2009089508-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | CASP7, CASP3, CASP6 | CYP11B2 4399/4885CYP11B1 4013/4885EGLN2 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.